U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07466901) titled 'A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer' on March 09.
Brief Summary: This study is a single-arm, open-label, multicenter, exploratory clinical trial aimed at observing and evaluating the efficacy and safety of camrelizumab combined with famitinib in the adjuvant treatment of cervical cancer patients after surgery.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Cervical Cancer
Radical Surgery
Adjuvant Therapy
Intervention:
DRUG: Camrelizumab
200mg, intravenous drip for 0.5h, Q3W
DRUG: famotinib...